
RxSight (RXST) Stock Forecast & Price Target
RxSight (RXST) Analyst Ratings
Bulls say
RxSight is expected to experience growth in the second half of 2026, driven by increased utilization and a focus on LALs. The company's bull case scenario, which includes double-digit growth, corresponds to an estimated share price of $16, while its base case scenario has a target price of $11 based on steady recovery. While the company's 2Q26 results were disappointing, its collaboration with ALC and strong gross margins suggest potential for success in the future. Risks to this positive outlook include competition and potential financing rounds.
Bears say
RxSight is currently facing challenges with declines in utilization and margin contraction, which could lead to a decrease in revenue and profitability. These potential risks could be exacerbated by the company's reliance on a single reportable segment and its collaboration agreement with ALC, which may not be a strong indication of its PowerVision pipeline lens success. Without a significant improvement in utilization and margins, it's uncertain if RxSight can return to growth in the near future. Additionally, its valuation may be considered undemanding, but still relatively high compared to its current performance.
This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.
RxSight (RXST) Analyst Forecast & Price Prediction
Start investing in RxSight (RXST)
Order type
Buy in
Order amount
Est. shares
0 shares